TBCK and kidney cancer: Moreover, miR-1208 directly targets TBCK by interacting with two binding sites in the 3′-UTR, which is involved in miR-1208-induced apoptosis and, in turn, increases susceptibility to cisplatin or TRAIL in kidney cancer cells.